• NewAmsterdam Pharma Company N.V. has reported first-quarter 2026 results, posting US$3.04 million in sales and a net loss of US$48.44 million, while outlining ongoing Phase 3 programs for its lead drug obicetrapib.
• Investors also heard that an interim analysis of the PREVAIL cardiovascular outcomes trial is planned for late 2026, alongside pending European regulatory decisions and potential initial commercial launches of obicetrapib by Menarini.
• We will now examine how the planned PREVAIL interim analysis and broader obicetrapib pipeline updates may influence NewAmsterdam Pharma’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

What Is NewAmsterdam Pharma's Investment Narrative?

To own NewAmsterdam today, you have to believe obicetrapib can become a meaningful cardio‑metabolic franchise and that the company can bridge the gap between heavy R&D spending and future product revenue. The latest Q1 update reinforces that this is still a “pipeline story”: sales remain minimal while the net loss widened, and management is leaning on a strong US$707.3 million cash position and equity tools such as expanded share issuance and an employee stock plan. The real swing factors are unchanged but now more time‑stamped: the PREVAIL interim readout planned for late 2026, European regulatory decisions in the second half of 2026, and Menarini’s potential initial launches. The PREVAIL interim plan and broader Phase 3 progress support these catalysts, but also sharpen the risk if outcomes or timelines disappoint.

However, the planned share issuance authority could matter more than it first appears. NewAmsterdam Pharma's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span from about US$49 to a very large figure, underlining how far opinions diverge. Set this against PREVAIL’s binary interim outcome and funding needs, and you can see why taking in multiple viewpoints before committing fresh capital really matters here.

Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be worth just $49.81!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.